Metabolic syndrome lab panel: the five-marker pattern most doctors don't fully explain
Anchor biomarkers: Triglycerides, HDL, fasting glucose, blood pressure, waist circumference
TL;DR
- •Metabolic syndrome is defined by a pattern, not a single number. Three out of five criteria — elevated triglycerides, low HDL, elevated fasting glucose, elevated blood pressure, increased waist circumference — meet the threshold.
- •Most patients with metabolic syndrome are told only "you should lose some weight." That misses the actual physiology: insulin resistance driving every one of the five markers.
- •The trig-to-HDL ratio is the single most underused metabolic marker in primary care. It tracks insulin resistance years before glucose moves.
The five diagnostic criteria
| Marker | Reference range | What it means |
|---|---|---|
| Waist circumference | > 40 in (men) / > 35 in (women) | Visceral adiposity — the metabolically active fat around organs. |
| Triglycerides | ≥ 150 mg/dL | Rises with insulin resistance; the earliest lipid marker to move. |
| HDL cholesterol | < 40 mg/dL (men) / < 50 mg/dL (women) | Drops with insulin resistance. |
| Blood pressure | ≥ 130 / 85 mmHg | Insulin resistance contributes to vascular tone and sodium retention. |
| Fasting glucose | ≥ 100 mg/dL | The latest marker to move; reflects pancreatic strain. |
| Fasting insulin (upstream) | < 10 µIU/mL (optimal < 5) | The engine. Often elevated 5–10 years before glucose moves. |
| HOMA-IR (upstream) | < 1.5 | Quantifies insulin resistance directly. |
| Triglyceride / HDL ratio (upstream) | < 2.0 | The single best metabolic risk discriminator in adults. |
| ApoB | < 90 mg/dL (general) | The cholesterol number that actually tracks cardiovascular risk in metabolic syndrome. |
| hs-CRP | < 1.0 mg/L | Inflammation rides with metabolic syndrome. |
| Liver enzymes (ALT) | < 25 IU/L | Non-alcoholic fatty liver (NAFLD) is the hepatic version of the same insulin resistance. |
Diagnosis = any 3 of the first 5 (NCEP ATP III criteria). The lower rows are upstream markers that often shift years before the diagnostic criteria do — the physiology that the formal definition doesn't fully capture.
Three real patterns Phi has seen
Example patterns · synthetic data drawn from Phi's scenario library. Not real patient records.
Pattern 1 — "Three out of five, BMI 28, told to lose weight."
Triglycerides 178. HDL 38. Fasting glucose 102. BP 132/86. Waist 41 inches. Five out of five criteria met. Fasting insulin 21. HOMA-IR 5.1. ApoB 115. ALT 38 (high-normal). The standard advice: "lose weight, eat better." The Phi read: this is full metabolic syndrome with measurable insulin resistance, early fatty liver, and elevated cardiovascular risk. The intervention plan should explicitly target insulin sensitivity (resistance training, post-meal walking, protein priority, sleep ≥ 7 hours) — not just calorie restriction.
Example pattern · synthetic data
Pattern 2 — "Skinny" metabolic syndrome / TOFI.
Triglycerides 162. HDL 41. Fasting glucose 98. BP 128/82. Waist 36 inches. BMI 23 (normal weight). Three out of five criteria. Fasting insulin 16. HOMA-IR 3.7. The patient is told "you're fine, your BMI is normal." The reality: visceral adiposity drives metabolic dysfunction independent of overall body weight. This patient has the same cardiovascular risk as someone 40 pounds heavier with the same lab pattern. Resistance training, dietary protein priority, and sleep work are the typical first-line levers.
Example pattern · synthetic data
Pattern 3 — Six months of focused intervention.
Triglycerides 92 (was 178). HDL 54 (was 38). Fasting glucose 89 (was 102). BP 118/74 (was 132/86). Waist 37 (was 41). Zero out of five criteria. Fasting insulin 6 (was 21). HOMA-IR 1.3 (was 5.1). ALT 22 (was 38). The intervention: walking 30 min/day after meals, resistance training 3x/week, protein at every meal, 7+ hours sleep, removing late-evening eating. No medications. The trajectory across every marker is what reversal looks like — and most metabolic-syndrome patients can achieve it with consistent inputs.
Example pattern · synthetic data
Questions to bring to your doctor
- Where do I sit on each of the five diagnostic criteria, and how have those numbers moved over the last 3 years?
- Have we checked fasting insulin, HOMA-IR, and the triglyceride-to-HDL ratio?
- What's my ApoB? It's a stronger cardiovascular risk predictor than LDL in metabolic syndrome.
- Should we be screening for non-alcoholic fatty liver (ALT, AST, GGT, possibly ultrasound)?
- What's the actionable lifestyle plan beyond "diet and exercise" — what specific interventions have you seen work for your patients with this pattern?
- Should I be on a statin given my metabolic risk profile, even with "normal" LDL?
- What's my realistic 6-month trajectory if I commit to specific changes?
What Phi adds beyond a single number
Metabolic syndrome is a five-marker pattern, but the *biology* is one process: insulin resistance affecting multiple systems. Phi reads all five diagnostic criteria *plus* the upstream insulin and inflammation markers *plus* the cardiovascular and liver implications — together, and across every panel you've ever uploaded. The integrated picture tells you not just whether you meet the diagnosis, but how far upstream or downstream you are, and which markers are moving on the interventions you're trying.
Upload your most recent lab report. Phi will pull out every metabolic-relevant marker, compare them against optimal (not just reference) ranges, flag the pattern, and tell you what to ask at your next appointment.
Frequently asked questions
If I only have 2 out of 5 criteria, am I safe?
Not exactly — but you don't meet formal diagnosis. Two-out-of-five with elevated fasting insulin or HOMA-IR is essentially "metabolic syndrome in progress" and warrants the same lifestyle attention. The diagnostic threshold is a clinical convention, not a physiologic step-change.
Can metabolic syndrome reverse?
Yes — frequently, with consistent lifestyle change. Trial data show that 30–60% of patients can move off the diagnostic criteria within 6–12 months of targeted intervention. Insulin resistance reversal is among the highest-success-rate interventions in chronic disease.
Do I need medication?
It depends on the specific markers and your cardiovascular risk profile. Statins are reasonable for many patients with elevated ApoB and other risk factors. Metformin can be helpful for documented insulin resistance. SGLT2 inhibitors and GLP-1 agonists are increasingly used. But for most patients, lifestyle interventions deliver substantial gains before medications become first-line.
What's the difference between metabolic syndrome and prediabetes?
Prediabetes is one criterion (elevated fasting glucose or HbA1c) of metabolic syndrome. Many prediabetic patients meet 3+ metabolic syndrome criteria; many metabolic syndrome patients haven't yet crossed into prediabetic glucose. The conditions overlap heavily but aren't identical.
Why does my doctor focus on LDL when ApoB seems more useful?
LDL has decades of guideline momentum. ApoB is increasingly preferred by cardiologists for risk assessment, especially in patients with metabolic dysfunction where LDL particle size and number matter more than total LDL mass. Ask your doctor to add ApoB to your next lipid draw.
Is fatty liver a separate condition or part of metabolic syndrome?
Non-alcoholic fatty liver disease (NAFLD) is essentially the hepatic manifestation of the same insulin resistance. Most NAFLD patients have metabolic syndrome features and vice versa. Liver enzymes are worth tracking.
Does sleep really affect metabolic syndrome?
Yes — substantially. Sleep deprivation acutely worsens insulin sensitivity, increases evening cortisol, raises appetite hormones (ghrelin), and lowers satiety hormones (leptin). Chronic short sleep is an independent risk factor for metabolic syndrome and T2D. Seven-plus hours is a primary intervention, not optional.
References
All citations verified against PubMed / publisher of record 2026-05-25.
- 1.Grundy SM, Cleeman JI, Daniels SR, et al. (American Heart Association; National Heart, Lung, and Blood Institute). (2005). Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 112(17):2735-2752. — The AHA/NHLBI statement that defines the 5-criteria diagnostic framework used on this page (waist circumference, triglycerides, HDL, BP, fasting glucose; any 3 of 5 for diagnosis).PubMed →DOI →
- 2.American Diabetes Association Professional Practice Committee. (2024). Standards of Care in Diabetes—2024. Diabetes Care. 47(Suppl 1):S1-S321. — Reference for the fasting glucose ≥ 100 mg/dL threshold used in metabolic syndrome criteria (aligned with the ADA impaired-fasting-glucose cutoff).DOI →
- 3.Knowler WC, Barrett-Connor E, Fowler SE, et al. (Diabetes Prevention Program Research Group). (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 346(6):393-403. — DPP: lifestyle reduced T2D incidence by 58%, metformin by 31%. Reversal-trajectory framing on this page.PubMed →DOI →
- 4.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28(7):412-419. — HOMA-IR derivation.PubMed →DOI →
- 5.McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. (2003). Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine. 139(10):802-809. — Trig/HDL ratio cutoff (3.0 US units) basis.PubMed →DOI →
- 6.Grundy SM, Stone NJ, Bailey AL, et al. (2019). 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 73(24):e285-e350. — Standard reference for LDL targets, ApoB framing, and cholesterol-lowering strategies referenced on this page. Co-published Circulation 139:e1082-1143.PubMed →DOI →
- 7.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. (2016). Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64(1):73-84. — Foundational meta-analysis on global NAFLD prevalence (25%) and its co-occurrence with metabolic syndrome (42.5%). Basis for the NAFLD-as-hepatic-manifestation framing.PubMed →DOI →
Specific functional / longevity-medicine targets ("fasting insulin optimal < 5 µIU/mL", "HOMA-IR < 1.5 optimal", "hs-CRP < 1.0 optimal", "ALT < 25 IU/L optimal") reflect practice positions rather than guideline cutoffs. Every link above opens the PubMed abstract or publisher's DOI landing page in a new tab. All citations verified vs PubMed / publisher of record 2026-05-26.
By Steve Pinedo
Co-founder, Phi Longevity
Last updated: 2026-05-26
Steve Pinedo is the Co-founder of Phi Longevity, the AI application that turns a confusing stack of lab reports, wearable data, and clinical notes into a single, integrated picture of your health. He started Phi Longevity to make proactive health and wellness far easier to achieve. He realized how difficult it was for clients to manage their own care, records and coordination so he assembled a comprehensive M.D. led clinical team behind the platform, packaging the proactive-care experience that delivered measurable outcomes (lower triglycerides, reduced body fat, improved LDL, balanced hormones, relief from long-running autoimmune conditions) for any patient with a complicated lab to use now with an application. More about Phi →